Loading clinical trials...
Loading clinical trials...
A Phase 1/2 Open-Label, Multicenter, Dose Escalation and Expansion Study of AVB-001, an Intraperitoneally Administered, Cell-Generated, Human IL-2 Immunotherapy in Patients With Platinum-Resistant, High-Grade, Serous Adenocarcinoma of the Ovary, Primary Peritoneum, or Fallopian Tube
Conditions
Interventions
AVB-001 (Dose Escalation Phase)
AVB-001 (Dose Expansion Phase)
Locations
5
United States
National Cancer Institute
Bethesda, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
UPMC Magee-Womens Hospital
Pittsburgh, Pennsylvania, United States
Women & Infants Hospital of Rhode Island
Providence, Rhode Island, United States
MD Anderson Cancer Center
Houston, Texas, United States
Start Date
December 9, 2022
Primary Completion Date
April 1, 2024
Completion Date
April 10, 2024
Last Updated
April 24, 2024
NCT06915025
NCT05080946
NCT04657068
NCT05281471
NCT05445778
NCT05129969
Lead Sponsor
Avenge Bio, Inc
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions